Zymeworks ZYME
NASDAQ ZYME
$29.40 -0.50 (-1.69%)
As of: Sep 4, 2026 · 2:39 PM EDT

Zymeworks (ZYME) Income towards Parent Company (2021 - 2026)

Zymeworks (ZYME) posted Income towards Parent Company of -$44.2 million for Q1 2026, down 7.17% sequentially from -$41.2 million in Q4 2025, and down 95.1% YoY from -$900.6 million in Q1 2025.

Analysis

Zymeworks (ZYME) Income towards Parent Company (2021 - 2026) Analysis & Trends

Zymeworks has reported Income towards Parent Company for 6 years, with the latest figure at -$44.2 million in Q1 2026.

  • Quarterly Income towards Parent Company fell 95.1% year-over-year to -$44.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$102.7 million (up 9.7% YoY) and the FY2025 annual result came in at -$81.1 million, up 33.88% from the prior year.
  • Income towards Parent Company declined to -$44.2 million in Q1 2026 per ZYME's latest filing, from -$41.2 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $309.4 million in Q4 2022 and troughed at -$72.6 million in Q1 2022.
  • A 5-year average of -$14.3 million and a median of -$29.8 million in 2024 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2023: Income towards Parent Company jumped 890.33% in 2022, then plunged 104.68% in 2023.
  • Over 5 years, Income towards Parent Company stood at $309.4 million in 2022, then slumped by 104.68% to -$14.5 million in 2023, then tumbled by 62.31% to -$23.5 million in 2024, then slumped by 75.31% to -$41.2 million in 2025, then decreased by 7.17% to -$44.2 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$44.2 million, -$41.2 million, and -$19.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn -
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn -
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn
10 Zymeworks 2.15 Bn 1.88 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -45.02 Mn
Mar 31, 2026 -44.16 Mn
Dec 31, 2025 -41.21 Mn
Sep 30, 2025 -19.60 Mn
Jun 30, 2025 2.32 Mn
Mar 31, 2025 -22.64 Mn
Dec 31, 2024 -23.51 Mn
Sep 30, 2024 -29.85 Mn
Jun 30, 2024 -37.69 Mn
Mar 31, 2024 -31.65 Mn
Dec 31, 2023 -14.48 Mn
Sep 30, 2023 -28.69 Mn
Jun 30, 2023 -51.15 Mn
Mar 31, 2023 -24.35 Mn
Dec 31, 2022 309.43 Mn
Sep 30, 2022 -47.85 Mn
Jun 30, 2022 -64.62 Mn
Mar 31, 2022 -72.63 Mn
Dec 31, 2021 -39.15 Mn
Sep 30, 2021 -60.58 Mn